The vaccine industry is facing the golden development period, and another pharmaceutical company is entering the track

[pharmaceutical network market analysis] in December 2019, China's vaccine management law was implemented, and the vaccine industry is expected to achieve healthy development According to the estimation of professional institutions, the domestic vaccine market scale in 2019 is about 31.1 billion yuan, which is expected to grow to 100 billion yuan in 10 years, with an average compound growth rate of about 11.20% At present, pharmaceutical companies looking forward to the golden development period of China's vaccine industry have also begun to take action The vaccine industry ushered in a golden period of development Since the second half of 2019, the vaccine industry has gradually recovered At the same time, with the issuance of the vaccine management law and the release of the technical guidelines for vaccine clinical comparability research, the threshold of the industry's production end and R & D end will be greatly increased, which is conducive to the healthy development of China's vaccine industry The industry believes that the current vaccine industry is ushering in a golden period of development On the one hand, the vaccine industry has high technical and financial barriers and belongs to the high prosperity field With the continuous upgrading of people's health concept, the demand for vaccines will continue to grow in the future On the other hand, the national policy supports the return of overseas technical talents In the future, more and more heavy-duty vaccine products may be listed one after another, and the market is facing the development opportunity of variety expansion The vaccine industry has a bright future It is estimated that the vaccine market scale will reach 31.1 billion yuan in 2019, which will increase to 100 billion yuan in ten years, more than tripling, with an average compound growth rate of 11.2% Another pharmaceutical company cut into the track On January 16, step pharmaceutical announced that the company invested RMB 61123600 to increase the capital of Nanjing huapai biomedical Co., Ltd after the completion of the capital increase, it accounted for 54.4% of the registered capital of Nanjing huapai and became the controlling shareholder of Nanjing huapai According to the announcement, Nanjing huapai has a mature and complete industrial chain of vaccine research and production, including Zhejiang Tianyuan as the main production body, Taizhou Saihua and Wuxi huapai as the main research body Regarding this capital increase, step pharmaceutical mentioned in the announcement that in order to realize the development plan of the company's transformation from sales type to scientific research type, from natural medicine to the whole pharmaceutical industry chain, and from localization to globalization, the company plans to enter the vaccine field The industry believes that step pharmaceutical will invest to enter the vaccine industry, or further enhance market competitiveness At present, vaccine industry leading enterprises with strict production control and outstanding R & D strength are ushering in the harvest period From the perspective of the enterprises that have disclosed the performance forecast for 2019, Kangtai biology, the leading domestic vaccine company, expects the company to achieve a net profit of 550 million to 590 million yuan in the whole year, an increase of 26.24% to 35.42% compared with 436 million yuan in the same period of last year Hualan bio is expected to achieve a net profit of 1.253 billion yuan to 1.367 billion yuan in 2019, up 10% to 20% year on year The performance growth mainly benefited from the stable growth of the company's blood products business and the large increase of sales revenue of the holding subsidiary's quadrivalent influenza vaccine It is estimated that in 2019, Zhifei biology will achieve a net profit of 2.25 billion yuan to 2.54 billion yuan, an increase of 55% to 75% over the same period of last year In 2019, the company continued to focus on vaccine and biological products research and development, production, sales, promotion, distribution and import vaccine agents In addition, Changchun hi tech, a leading vaccine enterprise, is expected to achieve 1.61 billion to 1.812 billion yuan in 2019, an increase of 60% to 80% over the same period last year According to the industry, Nanjing huapai, which was acquired by step pharmaceutical this time, has a complete industrial chain of vaccine R & D and production, as well as the brand support of step pharmaceutical itself At this time, it enters the track, and its future development prospects are also worth looking forward to.